A combined effect of immune checkpoint inhibitors and a CD40 agonistic antibody in a pancreatic cancer mouse model

被引：0
|
作者：
Ichikawa, Juri [1 ]
Kawano, Kuniyuki [1 ,2 ]
Kato, Shingo [1 ,3 ]
Kurotaki, Daisuke [1 ,4 ]
Kuroishikawa, Ryo [1 ]
Kawase, Wataru [1 ,5 ]
Yoshida, Haruka [1 ]
Hiroshima, Yukihiko [5 ]
Endo, Itaru [6 ]
Maeda, Shin [2 ]
Nakajima, Atsushi [3 ]
Tamura, Tomohiko [1 ]
机构：
[1] Yokohama City Univ, Dept Immunol, Yokohama, Kanagawa, Japan
[2] Yokohama City Univ, Dept Gastroenterol, Yokohama, Kanagawa, Japan
[3] Yokohama City Univ, Dept Gastroenterol & Hepatol, Yokohama, Kanagawa, Japan
[4] Kumamoto Univ, Lab Chromatin Org Immune Cell Dev, Kumamoto, Japan
[5] Kanagawa Canc Ctr, Res Inst, Ctr Canc Genome Med, Yokohama, Kanagawa, Japan
[6] Yokohama City Univ, Dept Gastrol Surg, Yokohama, Kanagawa, Japan
来源：
CANCER SCIENCE | 2024年 / 115卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
J-2009
引用
收藏
页码：763 / 763
页数：1
相关论文
共 50 条
  • [31] Enhancement of the Abscopal Effect in Radiation Therapy by In Situ Delivered CD40 Antibody in Pancreatic Adenocarcinoma
    Yasmin-Karim, S.
    Moreau, M.
    Kumar, R.
    Dougan, S.
    Ngwa, W.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : E629 - E629
  • [32] Agonistic CD40 antibody combined with chemotherapy drives TLR4/MyD88 independent regression of pancreatic tumors in a T cell dependent manner
    Byrne, Katelyn T.
    Vonderheide, Robert H.
    CANCER IMMUNOLOGY RESEARCH, 2015, 3 (10)
  • [33] Fcγ Receptor Dependency of Agonistic CD40 Antibody in Lymphoma Therapy Can Be Overcome through Antibody Multimerization
    White, Ann L.
    Dou, Lang
    Chan, H. T. Claude
    Field, Vikki L.
    Mockridge, C. Ian
    Moss, Kane
    Williams, Emily L.
    Booth, Steven G.
    French, Ruth R.
    Potter, Elizabeth A.
    Butts, Cherie
    Al-Shamkhani, Aymen
    Cragg, Mark S.
    Verbeek, J. Sjef
    Johnson, Peter W. M.
    Glennie, Martin J.
    Beers, Stephen A.
    JOURNAL OF IMMUNOLOGY, 2014, 193 (04): : 1828 - 1835
  • [34] Systemic immune response to a CD40 agonist antibody in nonhuman primates
    Caudell, David L.
    Dugan, Gregory O.
    Babitzki, Galina
    Schubert, Christine
    Braendli-Baiocco, Annamaria
    Wasserman, Ken
    Acona, Gonzalo
    Stern, Martin
    Passioukov, Alexandre
    Cline, J. Mark
    Charo, Jehad
    JOURNAL OF LEUKOCYTE BIOLOGY, 2024, 115 (06) : 1084 - 1093
  • [35] Agonistic Antibody to CD40 Boosts the Antitumor Activity of Adoptively Transferred T Cells In Vivo
    Liu, Chengwen
    Lewis, Carol M.
    Lou, Yanyan
    Xu, Chunyu
    Peng, Weiyi
    Yang, Yan
    Gelbard, Alexander H.
    Lizee, Gregory
    Zhou, Dapeng
    Overwijk, Willem W.
    Hwu, Patrick
    JOURNAL OF IMMUNOTHERAPY, 2012, 35 (03) : 276 - 282
  • [36] Identification and characterization of an antagonistic anti-mouse CD40 antibody
    Ralph, Kerry L. M.
    Panzenbeck, Mark
    Xiao, Haiguang
    Frego, Lee
    Bigwarfe, Tammy
    Waltz, Erica
    Grimaldi, Christine
    Last-Barney, Kathy
    Souza, Don
    Brodeur, Scott
    Nabozny, Gerald
    Fine, Jay S.
    Distler, Jorg H. W.
    Ramanujam, Meera
    JOURNAL OF IMMUNOLOGY, 2016, 196
  • [37] A DNA Hypomethylating Drug Alters the Tumor Microenvironment and Improves the Effectiveness of Immune Checkpoint Inhibitors in a Mouse Model of Pancreatic Cancer
    Gonda, Tamas A.
    Fang, Jarwei
    Salas, Martha
    Do, Catherine
    Hsu, Emily
    Zhukovskaya, Anna
    Siegel, Ariel
    Takahashi, Ryota
    Lopez-Bujanda, Zoila A.
    Drake, Charles G.
    Manji, Gulam A.
    Wang, Timothy C.
    Olive, Kenneth P.
    Tycko, Benjamin
    CANCER RESEARCH, 2020, 80 (21) : 4754 - 4767
  • [38] COMBINED IRREVERSIBLE ELECTROPORATION AND LOCAL CD40 AGONISM STIMULATE NEOANTIGEN SPECIFIC SYSTEMIC IMMUNE RESPONSES THAT INHIBIT LIVER METASTASIS IN AN ORTHOTOPIC PANCREATIC CANCER MODEL
    Narayanan, Jayanth Shankara
    White, Rebekah
    Hayashi, Tomoko
    Carson, Dennis
    Schoenberger, Stephen
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A900 - A900
  • [39] CD40 agonists—a promising new treatment for pancreatic cancer?
    Shreeya Nanda
    Nature Reviews Gastroenterology & Hepatology, 2011, 8 (6) : 300 - 300
  • [40] Combined effect of p53-armed oncolytic virus and immune checkpoint inhibitors in murine pancreatic cancer models
    Fujita, Shuto
    Tazawa, Hiroshi
    Kajiwara, Yoshinori
    Kikuchi, Satoru
    Kuroda, Shinji
    Noma, Kazuhiro
    Urata, Yasuo
    Kagawa, Shunsuke
    Fujiwara, Toshiyoshi
    CANCER SCIENCE, 2025, 116 : 961 - 961
12345